Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status: | Completed |
---|---|
Conditions: | High Blood Pressure (Hypertension) |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | 6 - 17 |
Updated: | 4/21/2016 |
Start Date: | June 2010 |
End Date: | August 2014 |
A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
This double-blind 8 week study will evaluate dose response, efficacy (blood pressure
lowering effect) and safety of aliskiren in children 6 - 17 years old with hypertension at
low, mid and high weight-based doses. The low dose ranges from 6.25 mg to 25 mg of
aliskiren, the mid dose ranges from 37.5 mg to 150 mg of aliskiren and the high dose ranges
from 150 mg to 600 mg of aliskiren. This study is being conducted to support monotherapy
registration of aliskiren for the treatment of hypertension in children 6-17 years of age.
lowering effect) and safety of aliskiren in children 6 - 17 years old with hypertension at
low, mid and high weight-based doses. The low dose ranges from 6.25 mg to 25 mg of
aliskiren, the mid dose ranges from 37.5 mg to 150 mg of aliskiren and the high dose ranges
from 150 mg to 600 mg of aliskiren. This study is being conducted to support monotherapy
registration of aliskiren for the treatment of hypertension in children 6-17 years of age.
Inclusion Criteria:
- Documented diagnosis of hypertension as defined in the NHLBI 4th Report, 2004
- msSBP (mean of 3 measurements) must be ≥ 95th percentile for age, gender and height,
at Visit 2 (randomization) measurement as defined by the NHLBI 4th Report, 2004
Exclusion Criteria:
- Patient receiving immunosuppressant medication (e.g. cyclosporine, MMF, etc) other
than oral/topical steroids, for any medical condition
- Current diagnosis of heart failure (NYHA Class II-IV) or history of cardiomyopathy or
obstructive valvular disease
- msSBP ≥ 25% above the 95th percentile
- Second or third degree heart block without a pacemaker
- AST/SGOT or ALT/SGPT >3 times the upper limit of the reference range
- Total bilirubin > 2 times the upper limit of the reference range
- Creatinine clearance < 30 mL/min/1.73m² (calculated using Modified Schwartz formula
to estimate glomerular filtration rate [GFR]), based on the serum creatinine
concentration obtained at the screening visit)
- WBC count < 3000/mm³
Other protocol-defined inclusion/exclusion criteria may apply
We found this trial at
25
sites
Novartis Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Novartis Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Novartis Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials